Prelude Therapeutics (PRLD) Other Working Capital Changes (2019 - 2026)

Prelude Therapeutics has disclosed Other Working Capital Changes across 8 years of filings, most recently posting $68000.0 for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $68000.0, down 93.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.6 million (up 1943.29% YoY), and the FY2025 annual result was $35.5 million, changed N/A from the prior year.
• Other Working Capital Changes came in at $68000.0 for Q1 2026 at Prelude Therapeutics, down from $34.4 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $34.4 million in Q4 2025 to a low of -$2.0 million in Q2 2022.
• The 5-year median for Other Working Capital Changes is $331000.0 (2025), against an average of $2.3 million.
• Across the five-year window, Other Working Capital Changes sank 281.13% in 2024 and soared 3659.83% in 2025, its largest moves.
• Prelude Therapeutics' Other Working Capital Changes stood at $431000.0 in 2022, then tumbled by 199.54% to -$429000.0 in 2023, then surged by 313.52% to $916000.0 in 2024, then jumped by 3659.83% to $34.4 million in 2025, then slumped by 99.8% to $68000.0 in 2026.
• The last three Other Working Capital Changes figures came in at $68000.0 (Q1 2026), $34.4 million (Q4 2025), and -$287000.0 (Q3 2025), per Business Quant data.